KYORIN Pharmaceutical (4569) · InitiativeDropped
Out-Licensing Lascofloxacin to Nanjing Ninghe in China
First written in FY2023. 1 of 2 entries say "Dropped", first in FY2024-Q2. Latest entry: FY2024-Q2.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Termination of the China technology transfer agreement for lascufloxacin with 南京寧和A theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024-Q2DroppedAnnual report
「The following material contracts were terminated during the second quarter of the current consolidated fiscal year. ① Technology licensing Contract company: Kyorin Pharmaceutical Co., Ltd. (the Company) Licensed product: Lascufloxacin Counterparty: Nanjing Ninghe Country: China Contract year: 2022 Contract term: 15 years from the launch date plus automatic renewal」
The China licensing agreement for lascufloxacin with Nanjing Ninghe was terminated. - FY2023First statedAnnual report
「Lascofloxacin; Nanjing Ninghe; China; upfront fee, development milestones, sales milestones, royalties at a specified rate and supply price; 2022; 15 years from launch plus automatic renewal.」
A 2022 out-licensing agreement for lascofloxacin was signed with Nanjing Ninghe in China for a 15-year term from launch.